Indofarma Tbk
PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutic… Read more
Market Cap & Net Worth: Indofarma Tbk (INAF)
Indofarma Tbk (JK:INAF) has a market capitalization of $24.00 Million (Rp390.51 Billion) as of March 19, 2026. Listed on the JK stock exchange, this Indonesia-based company holds position #31553 globally and #608 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Indofarma Tbk's stock price Rp126.00 by its total outstanding shares 3099267500 (3.10 Billion).
Indofarma Tbk Market Cap History: 2015 to 2026
Indofarma Tbk's market capitalization history from 2015 to 2026. Data shows change from $32.00 Million to $24.00 Million (-0.30% CAGR).
Index Memberships
Indofarma Tbk is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Jakarta Stock Exchange Composite Index
JKSE
|
$148.31 Billion | 0.00% | #556 of 864 |
Weight: Indofarma Tbk's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Indofarma Tbk Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Indofarma Tbk's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Indofarma Tbk's market cap is 0.00 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $32.00 Million | $1.62 Trillion | $6.57 Billion | 0.00x | 0.00x |
| 2016 | $891.54 Million | $1.67 Trillion | -$17.37 Billion | 0.00x | N/A |
| 2017 | $1.12 Billion | $1.63 Trillion | -$46.28 Billion | 0.00x | N/A |
| 2018 | $1.24 Billion | $1.59 Trillion | -$32.74 Billion | 0.00x | N/A |
| 2019 | $165.74 Million | $1.36 Trillion | $7.96 Billion | 0.00x | 0.02x |
| 2020 | $767.72 Million | $1.72 Trillion | $27.58 Million | 0.00x | 27.84x |
| 2021 | $424.82 Million | $2.90 Trillion | -$37.57 Billion | 0.00x | N/A |
| 2022 | $219.08 Million | $1.14 Trillion | -$428.49 Billion | 0.00x | N/A |
| 2023 | $110.49 Million | $523.60 Billion | -$720.99 Billion | 0.00x | N/A |
| 2024 | $24.00 Million | $210.38 Billion | -$334.49 Billion | 0.00x | N/A |
Competitor Companies of INAF by Market Capitalization
Companies near Indofarma Tbk in the global market cap rankings as of March 19, 2026.
Key companies related to Indofarma Tbk by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Indofarma Tbk Historical Marketcap From 2015 to 2026
Between 2015 and today, Indofarma Tbk's market cap moved from $32.00 Million to $ 24.00 Million, with a yearly change of -0.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Rp24.00 Million | 0.00% |
| 2025 | Rp24.00 Million | 0.00% |
| 2024 | Rp24.00 Million | -78.28% |
| 2023 | Rp110.49 Million | -49.57% |
| 2022 | Rp219.08 Million | -48.43% |
| 2021 | Rp424.82 Million | -44.67% |
| 2020 | Rp767.72 Million | +363.22% |
| 2019 | Rp165.74 Million | -86.62% |
| 2018 | Rp1.24 Billion | +10.17% |
| 2017 | Rp1.12 Billion | +26.07% |
| 2016 | Rp891.54 Million | +2685.71% |
| 2015 | Rp32.00 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Indofarma Tbk was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.00 Million USD |
| MoneyControl | $24.00 Million USD |
| MarketWatch | $24.00 Million USD |
| marketcap.company | $24.00 Million USD |
| Reuters | $24.00 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.